TY  - JOUR
AU  - Mai, E. K.
AU  - Bertsch, U.
AU  - Dürig, J.
AU  - Kunz, C.
AU  - Haenel, M.
AU  - Blau, I. W.
AU  - Munder, M.
AU  - Jauch, A.
AU  - Schurich, B.
AU  - Hielscher, T.
AU  - Merz, M.
AU  - Huegle-Doerr, B.
AU  - Seckinger, A.
AU  - Hose, D.
AU  - Hillengass, J.
AU  - Raab, M. S.
AU  - Neben, K.
AU  - Lindemann, H-W
AU  - Zeis, M.
AU  - Gerecke, C.
AU  - Schmidt-Wolf, I. G. H.
AU  - Weisel, K.
AU  - Scheid, C.
AU  - Salwender, H.
AU  - Goldschmidt, H.
TI  - Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
JO  - Leukemia
VL  - 29
IS  - 8
SN  - 1476-5551
CY  - Basingstoke
PB  - Nature Publ. Group
M1  - DKFZ-2017-03074
SP  - 1721 - 1729
PY  - 2015
AB  - We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to ⩾VGPR rates (37.0 versus 34.3
KW  - Boronic Acids (NLM Chemicals)
KW  - Pyrazines (NLM Chemicals)
KW  - Bortezomib (NLM Chemicals)
KW  - Dexamethasone (NLM Chemicals)
KW  - Doxorubicin (NLM Chemicals)
KW  - Cyclophosphamide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25787915
DO  - DOI:10.1038/leu.2015.80
UR  - https://inrepo02.dkfz.de/record/127048
ER  -